Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Moderate Buy” from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $19.33.

VYGR has been the topic of several recent research reports. Guggenheim initiated coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price objective on the stock. Citigroup initiated coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 price objective on the stock. HC Wainwright started coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective on the stock. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Finally, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th.

Voyager Therapeutics Stock Performance

VYGR stock opened at $7.74 on Thursday. Voyager Therapeutics has a fifty-two week low of $6.06 and a fifty-two week high of $14.34. The business’s 50-day moving average is $8.79 and its two-hundred day moving average is $7.95. The company has a market cap of $420.28 million, a price-to-earnings ratio of 2.50 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The company had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Equities analysts predict that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new position in Voyager Therapeutics during the 3rd quarter valued at approximately $25,000. Ameritas Investment Partners Inc. purchased a new position in Voyager Therapeutics during the 2nd quarter valued at approximately $30,000. AJOVista LLC purchased a new position in Voyager Therapeutics during the 4th quarter valued at approximately $39,000. UBS Group AG purchased a new position in Voyager Therapeutics during the 1st quarter valued at approximately $39,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Voyager Therapeutics during the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.